Aim: To evaluate the diagnostic value of MOG-IgG antibodies in multiple sclerosis (MS) and acute disseminated encephalomyelitis (ADEM).
Material And Methods: Twenty-nine patients with definitive MS according to the criteria of McDonald, 2010 (21 with relapse-remitting MS and 8 with secondary progressive MS), 7 patients with ADEM confirmed by clinical and instrumental data and 27 healthy volunteers were included in the study. Serum MOG-IgG levels were evaluated in all patients. MOG-IgG levels in the cerebrospinal fluid (CSF) were evaluated in 22 cases with MS, 6 cases with ADEM, and 8 healthy volunteers using ELISA.
Results And Conclusions: Serum MOG-IgG levels are significantly higher in patients with MS and ADEM compared to the control group. No statistically significant differences in the serum MOG-IgG levels were found between MS and ADEM groups. When analyzing the level of MOG-IgG in CSF, no statistically significant between-group differences were obtained. The sensitivity and specificity of the determination of MOG-IgG in serum in patients with MS are 75,8% and 92.59%, respectively. MOG-IgG is detected in serum and CSF in patients with demyelinating diseases that indicates its pathogenetic significance in the development of MS and ADEM. Serum MOG-IgG may be a valuable biomarker for demyelinating diseases. Further research in a large population of patients is required.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17116/jnevro20191192218 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MOG IgG antibody positivity from laboratory to clinical practice: A real world experience.
Mult Scler Relat Disord
December 2024
Department of Pediatric Cardiology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidhyapeetham, Ponekkara PO, Kochi 682041, Kerala, India.
Background And Objectives: Myelin oligodendrocyte glycoprotein (MOG) associated disease (MOGAD) is an antibody-mediated inflammatory demyelinating disorder of the CNS with varied presentations like optic neuritis (ON), transverse myelitis, and cortical encephalitis. This study aims to highlight the significance of low MOG IgG antibody positivity and its diagnostic implications in a real-world cohort.
Methods: In this retrospective observational study, serum and CSF from suspected MOGAD cases were tested at a tertiary healthcare centre's Neuroimmunology Laboratory.
Neurofilament Light Chain as a Discriminator of Disease Activity Status in MOG Antibody-Associated Disease.
Neurol Neuroimmunol Neuroinflamm
January 2025
Department of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland.
Background And Objectives: In patients with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD), acute disease activity is generally identified through medical history, neurologic examination, and imaging. However, these may be insufficient for detecting disease activity in specific conditions. This study aimed to investigate the dynamics of serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) after clinical attacks and to assess their utility in discriminating attacks from remission in patients with MOGAD.
View Article and Find Full Text PDFMOG-IgG is rare in AQP4-IgG seronegative NMO phenotype in Brazil.
Mult Scler Relat Disord
December 2024
CIEM MS Research Center, Federal University of Minas Gerais Medical School, Belo Horizonte, MG, Brazil.
Background: Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease most frequently characterized by a neuromyelitis optica (NMO) phenotype, comprising both simultaneous or sequential optic neuritis (ON) and longitudinally extensive transverse myelitis (LETM). Symptoms of brainstem, diencephalic and cerebral involvement may also occur. While most NMOSD patients test positive for serum aquaporin-4 (AQP4) antibodies, some seronegative patients test positive for oligodendrocyte glycoprotein-IgG (MOG-IgG).
View Article and Find Full Text PDF[Clinical and imaging characteristics and influencing factors of myelin oligodendrocyte glycoprotein antibody-associated disease with different IgG antibody conversions].
Zhonghua Yi Xue Za Zhi
December 2024
Department of Neurology, Beijing Tongren Hospital, Capital Medical University, Beijing100730, China.
To investigate the clinical and imaging characteristics of patients with myelin oligodendrocyte glycoprotein antibody (MOG-IgG)-associated disease (MOGAD) with different MOG-IgG seroconversions, and to analyze the factors affecting the conversion. Retrospective study. Patients diagnosed with MOGAD in the Department of Neurology, Beijing Tongren Hospital, Capital Medical University from January 2019 to April 2023 were included and the follow-up ended in May 2024.
View Article and Find Full Text PDFClinical, Lab, and Radiological Evolution of an Adult Patient With Unilateral Cortical Lesion in Anti-Myelin Oligodendrocyte Glycoprotein (MOG)-Associated Encephalitis With Seizures and Anti-Glial Fibrillary Acidic Protein (GFAP) Positive Antibodies.
Cureus
September 2024
Neurology, General Hospital of Athens G. Gennimatas, Athens, GRC.
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease refers to a clinical and radiological spectrum of demyelinating disorders of the Central Nervous System. We report the case of a female adult patient presenting to our department with an episode of seizures and cognitive dysfunction, compatible with Gerstmann syndrome. Brain MRI revealed a high T2 and DWI signal unilateral cortical lesion at the inferior left parietal lobe and leptomeningeal contrast enhancement.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!